4771 studies found for:    leukemia
Show Display Options
Rank Status Study
1 Completed
Has Results
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
Condition: Leukemia
Interventions: Drug: Dasatinib;   Drug: BMS-833923
2 Unknown  Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL
Interventions: Drug: Revlimid, rituximab;   Drug: Relapsed or refractory CLL. Lenalidomide and Rituximab
3 Active, not recruiting Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation
Condition: Chronic Lymphocytic Leukemia
Intervention: Procedure: Leukemia cell harvest
4 Terminated
Has Results
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Condition: Leukemia
Interventions: Biological: bcr-abl peptide vaccine;   Genetic: reverse transcriptase-polymerase chain reaction
5 Terminated Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation
Conditions: Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts
Intervention: Biological: GM-K562/leukemia cell vaccine
6 Completed Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia
Interventions: Biological: PR1 leukemia peptide vaccine;   Drug: Montanide ISA 51 VG;   Biological: sargramostim;   Other: laboratory biomarker analysis
7 Terminated Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Conditions: Minimal Residual Disease;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine;   Drug: Cytarabine;   Drug: Methotrexate
8 Completed Collection and Banking of Leukemia Cells MDS/AML
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Intervention: Other: Collection of Leukemia Cells
9 Unknown  Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Conditions: Leukemias;   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Adult T Cell Leukemia (ATL);   Chronic Myeloid Leukemia (CML-BP);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: Terameprocol (EM-1421)
10 Active, not recruiting Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water
Condition: Chronic Lymphocytic Leukemia
Intervention:
11 Not yet recruiting An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
Condition: Leukemia
Interventions: Drug: MEK-162;   Drug: Nilotinib;   Behavioral: Questionnaires
12 Unknown  Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Myeloproliferative Disorders;   Acute Lymphocytic Leukemia;   Acute Promyelocytic Leukemia;   Acute Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Juvenile Myelomonocytic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide
13 Terminated A Study for Patients With Acute Leukemia
Condition: Acute Leukaemia
Intervention: Drug: LY2523355
14 Active, not recruiting Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
15 Recruiting Acute Lymphoblastic Leukemia Registry at Asan Medical Center
Conditions: Leukemia, Acute Lymphoblastic;   Precursor B-Cell Lymphoblastic Leukemia;   Leukemia, Biphenotypic, Acute;   Leukemia, Lymphoblastic, Acute, Philadelphia-Positive;   Lymphoblastic Lymphoma
Intervention: Other: Diagnosed as ALL
16 Active, not recruiting Genetic Study of Chronic Lymphocytic Leukemia Families
Condition: Leukemia
Intervention: Behavioral: Questionnaire
17 Withdrawn Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Conditions: Leukemia;   Acute Lymphocytic Leukemia
Intervention: Drug: Velcade
18 Not yet recruiting Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)
Condition: Leukemia
Interventions: Drug: Ofatumumab;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Behavioral: Phone Calls
19 Completed
Has Results
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
Conditions: Large Granular Lymphocytic Leukemia;   LGL Leukemia
Interventions: Drug: Cyclosporine;   Genetic: Gene expression analysis;   Genetic: Microarray analysis;   Other: Laboratory biomarker analysis
20 Active, not recruiting Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Condition: Leukemia
Interventions: Drug: Etoposide, Mitoxantrone, Clofarabine;   Drug: Clofarabine, Etoposide, Mitoxantrone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years